Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 open-label single-arm mavacamten in symptomatic obstructive hypertrophic cardiomyopathy (Japan)
jRCT2031220178Phase 3Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Aug 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of mavacamten in hypertrophic cardiomyopathy (HCM), sponsored by Bristol Myers Squibb. Primary endpoint: Change in post-exercise LVOT peak gradient at Week 30. Started Aug 2022; status: completed.
02
Drugs
mavacamten
03
Conditions
hypertrophic cardiomyopathy (HCM)
Beyond the preview
Go deeper on jRCT2031220178.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031220178.